Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption
- PMID: 18758913
- DOI: 10.1007/s11060-008-9667-5
Primary meningeal CNS lymphoma treated with intra-arterial chemotherapy and blood-brain barrier disruption
Abstract
Diffuse large B-cell lymphoma of the meninges is a particularly rare form of primary CNS lymphoma. We report a case of a 63-year-old woman found to have primary meningeal lymphoma (PML) with dural and leptomeningeal involvement whom we treated with multiple cycles of intra-arterial (IA) methotrexate, intravenous (IV) etoposide phosphate, and IV cyclophosphamide after reversible osmotic blood-brain barrier disruption (BBBD). Improvement was evident on gadolinium-enhanced brain MRI one month into therapy. At 67 months post-diagnosis there is no evidence of CNS disease. After completing her therapy regimen, she remained disease-free for 34 months, when stage IV diffuse large B-cell lymphoma was discovered in her left adrenal gland and right thigh. Following six cycles of rituximab and CHOP treatment, she is presently in complete remission. IA methotrexate and reversible osmotic BBBD without radiation therapy may be an effective therapy for treating PML.
Similar articles
-
Current status and future of relapsed primary central nervous system lymphoma (PCNSL).Leuk Lymphoma. 2003 Apr;44(4):627-33. doi: 10.1080/1042819021000055057. Leuk Lymphoma. 2003. PMID: 12769339
-
Imaging and therapy with rituximab anti-CD20 immunotherapy in an animal model of central nervous system lymphoma.Clin Cancer Res. 2011 Apr 15;17(8):2207-15. doi: 10.1158/1078-0432.CCR-10-2923. Epub 2011 Mar 8. Clin Cancer Res. 2011. PMID: 21385922 Free PMC article.
-
The potential for complete and durable response in nonglial primary brain tumors in children and young adults with enhanced chemotherapy delivery.Cancer J Sci Am. 1998 Mar-Apr;4(2):110-24. Cancer J Sci Am. 1998. PMID: 9532413
-
[Chemotherapy in conjunction with blood brain barrier disruption in the treatment of primary central nervous system lymphoma].Duodecim. 2013;129(15):1563-70. Duodecim. 2013. PMID: 24163974 Review. Finnish.
-
Impact of central nervous system (CNS) prophylaxis on the incidence and risk factors for CNS relapse in patients with diffuse large B-cell lymphoma treated in the rituximab era: a single centre experience and review of the literature.Br J Haematol. 2012 Oct;159(1):39-49. doi: 10.1111/j.1365-2141.2012.09247.x. Epub 2012 Jul 31. Br J Haematol. 2012. PMID: 22849793 Review.
Cited by
-
Primary leptomeningeal lymphoma: International Primary CNS Lymphoma Collaborative Group report.Neurology. 2013 Nov 5;81(19):1690-6. doi: 10.1212/01.wnl.0000435302.02895.f3. Epub 2013 Oct 9. Neurology. 2013. PMID: 24107866 Free PMC article.
-
Dural MALT lymphoma with disseminated disease.Hematol Rep. 2010 Jan 26;2(1):e10. doi: 10.4081/hr.2010.e10. Epub 2010 Dec 3. Hematol Rep. 2010. PMID: 22184513 Free PMC article.
-
Blood-Brain Barrier Disruption in Neuro-Oncology: Strategies, Failures, and Challenges to Overcome.Front Oncol. 2020 Sep 18;10:563840. doi: 10.3389/fonc.2020.563840. eCollection 2020. Front Oncol. 2020. PMID: 33072591 Free PMC article. Review.
-
Primary diffuse large B-cell lymphoma of the dura mimicking a meningioma with intervening skull bone invasion.J Neurooncol. 2014 Oct;120(1):215-7. doi: 10.1007/s11060-014-1530-2. Epub 2014 Jul 10. J Neurooncol. 2014. PMID: 25005530 No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials